PACB — Pacific Biosciences of California, Inc.

Summary of PacBio Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $37.2 million, flat year-over-year.
• Instrument Revenue: $9.7 million, down 12% from $11 million in Q1 2025.
• Consumable Revenue: Record $21.8 million, up 9% from $20.1 million in Q1 2025.
• Non-GAAP Gross Profit: $13.8 million, with a gross margin of 37%, down from 40% in Q1 2025.
• Non-GAAP Operating Expenses: $49.9 million, a 19% decrease from $61.7 million in Q1 2025.
• Non-GAAP Net Loss: $35.9 million ($0.12 per share), improved from a loss of $44.4 million ($0.15 per share) in Q1 2025.
• Cash Position: Approximately $276 million, down from $280 million at the end of 2025.

2. Strategic Updates and Business Highlights

• Achieved record consumable revenue for the third consecutive quarter, with over 100% year-over-year growth in shipments to clinically focused accounts.
• Launched a significant AI-related project with Basecamp Research to sequence 100,000 metagenomic samples, aiming to create a Trillion Gene Atlas.
• Completed the sale of short-read sequencing assets to Illumina for $48.1 million, strengthening the balance sheet.
• Strong demand for the SPRQ-Nx early access program, with expectations for increased clinical shipments as customers transition to full commercialization.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Revised to a range of $165 million to $175 million, lowering the high end by $5 million due to softer Vega demand and academic funding challenges.
• Expect non-GAAP gross margin improvement towards the lower end of the previously communicated range of 100 to 400 basis points.
• Anticipate continued growth in consumables driven by clinical customers and the expansion of the Revio and Vega installed base.

4. Bad News, Challenges, or Points of Concern

• Instrument revenue, particularly from the Vega platform, was lower than expected due to ongoing pressure from academic funding and promotional pricing strategies.
• Revenue in Asia Pacific declined 16% year-over-year, attributed to customers waiting for the SPRQ-Nx launch.
• Non-GAAP gross margin decline was impacted by increased computing component costs and temporary promotional pricing for Vega.
• Visibility into future consumable revenue is primarily based on existing customer utilization rather than new placements.

5. Notable Q&A Insights

• Management indicated that the guidance for instruments reflects strengthening demand for Revio systems, while Vega remains sensitive to funding environments.
• Clinical traction is strong in EMEA, with growth driven by rare disease testing becoming first-line tests in several countries.
• The Vega promotional program successfully attracted new customers, but the academic funding environment remains a significant challenge, particularly in the U.S.
• Management emphasized the importance of the SPRQ-Nx launch in driving future growth and improving gross margins, with expectations for a return to normalized ASPs for Vega in Q2.

Overall, while PacBio reported strong consumable growth and strategic advancements, challenges in instrument sales and external funding pressures present ongoing risks to their outlook.